1. Home
  2. MCS vs CSTL Comparison

MCS vs CSTL Comparison

Compare MCS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCS

Marcus Corporation (The)

HOLD

Current Price

$30.69

Market Cap

676.9M

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$30.39

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCS
CSTL
Founded
1935
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
676.9M
722.8M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
MCS
CSTL
Price
$30.69
$30.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$23.33
$45.50
AVG Volume (30 Days)
225.2K
372.2K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
1.69%
N/A
EPS Growth
N/A
N/A
EPS
0.77
N/A
Revenue
$758,458,000.00
$344,229,000.00
Revenue This Year
$12.05
$2.42
Revenue Next Year
$3.15
$12.69
P/E Ratio
$37.79
N/A
Revenue Growth
3.11
3.66
52 Week Low
$12.85
$17.72
52 Week High
$29.75
$44.28

Technical Indicators

Market Signals
Indicator
MCS
CSTL
Relative Strength Index (RSI) 84.63 77.31
Support Level $14.96 $22.67
Resistance Level N/A $34.97
Average True Range (ATR) 1.08 1.48
MACD 0.72 0.45
Stochastic Oscillator 84.77 93.53

Price Performance

Historical Comparison
MCS
CSTL

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: